Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Nutanix Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Nutanix Inc trades at $55.65 (market cap $14.99B). The key difference: Nutanix Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| BIO | NTNX | |
|---|---|---|
Market Cap | $8.04B | $14.99B |
Sector | Health | Technology |
52-Week High | $339.75 | $81.12 |
52-Week Low | $241.71 | $34.41 |
Enterprise Value | $7.85B | $14.51B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Nutanix (NTNX) trades at $55.22, up 0.78% on the day, reflecting positive momentum. The stock exhibits a bullish technical trend with strong moving average support and is trading near key resistance at $56. Fundamentally, the company demonstrates robust revenue growth, with Q3 2026 results beating expectations, and maintains a high gross profit margin of 87.09%. Recent news highlights strategic partnerships and NVIDIA certification for its AI infrastructure solutions.
The outlook for NTNX is positive, driven by consistent earnings beats, strong analyst consensus (62.5% Buy ratings), and a $57.80 price target suggesting modest upside. Key risks include its high valuation multiples (P/E of 58.39) and execution challenges in a competitive cloud software market. Investor sentiment is buoyed by its positioning in hybrid multicloud and AI growth areas.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
